What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and rifapentine
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names rifapentine in its contraindications section; the rifapentine label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered.”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the rifapentine FDA label on DailyMed (effective February 6, 2026, sanofi-aventis U.S. LLC).
What does the nirmatrelvir/ritonavir label say about rifapentine?
Nirmatrelvir/ritonavir label, contraindicationsAntimycobacterials: rifampin, rifapentine
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: Antimycobacterial; Drugs within Class: rifampin, rifapentine; Effect on Concentration: ↓ nirmatrelvir/ritonavir; Clinical Comments: Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered [see ].
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the rifapentine label say about nirmatrelvir/ritonavir?
Rifapentine's label (effective February 6, 2026) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Priftin), sanofi-aventis U.S. LLC, effective February 6, 2026 (SPL set 3a64fb70-b85e-43d9-8bcd-7e893f568ae1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nirmatrelvir/ritonavir | Rifapentine | |
|---|---|---|
| Labeled for | COVID-19 | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $4.83 per tablet 150 mg tablet |
| Shortage now | No current entry | Resolved |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once